Hit enter to search or ESC to close
Broker: OCBC Investment Research Date of Report: 6 June 2025 Hong Kong and China Equities: Silver Linings Amid Market Volatility in 2025 US-China Trade Truce: A Temporary Lift for Market Sentiment Following a recent...
IPO Details Purpose of IPO Raising up to HKD 221 million through offering 10.585 million H-shares at HKD 18.9–20.9 per share. Use of proceeds: Expansion of production facilities in China, Thailand, and Indonesia. Working capital for...
IPO Details Purpose of IPO Offering 24.86 million shares at HKD 9.75 each, targeting HKD 242 million in proceeds. Intent is to expand AI capabilities, enhance analytics infrastructure, and scale staff and marketing Indicates a clear...
1. IPO Details Purpose of IPO Rongta is offering 18.40 million H-shares (16.56 M via international placement; 1.84 M public Hong Kong tranche). IPO proceeds (~HK$148 million at assumed mid-price) will be allocated to: 36.5% for expanding product...
IPO Details Listing date: 9 June 2025 at RM 0.16 IPO price, Target price: RM 0.20 IPO oversubscribed by 5.33× (196.2 M units applied for 31 M offered). Bumiputera public: 2.94×, Other Malaysian public: 7.72×.  Purpose of...
Broker: Maybank Investment Bank Berhad Date of Report: June 6, 2025 YTL Power Set for Re-Rating: AI Compute Launch, Robust Earnings, and ESG Initiatives Position Group for Growth Overview: YTL Power’s Strategic Evolution and...
UOB Kay Hian Private Limited Date of Report: 6 June 2025 Sembcorp Industries: Powering Ahead with Renewables, Singapore Grids, and Hydrogen Ambitions Overview: Sembcorp Industries’ Strategic Pivot and Growth Trajectory Sembcorp Industries (SCI), a...
Broker: UOB Kay Hian Date of Report: 6 June 2025 Malaysia Gaming Sector 2025: Depressed Valuations, Tempting Yields, and the Search for Catalysts Sector Overview: Defensive Appeal Amid Structural De-Rating The Malaysian gaming sector,...
Broker: UOB Kay Hian Date of Report: 6 June 2025 Duopharma Biotech: Riding the Insulin Wave – Robust Growth, Margin Upside, and Strategic Resilience for 2025 Overview: Duopharma Biotech’s Promising Outlook for Investors Duopharma...
Broker: UOB Kay Hian Date of Report: 6 June 2025 China’s Auto Industry 2025: Regulatory Shakeup, Innovation Race, and Top Stock Picks Executive Summary: Government Intervention and Market Outlook China’s automobile sector is undergoing...
